Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study

Area of Science:

• Neuroscience
• Neurology
• Radiology

Background:

• Huntington's disease (HD) is a neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric dysfunction.
• Dopamine D2 receptor dysfunction is implicated in the pathophysiology of HD, but its progression is not well understood.

Purpose of the Study:

• To investigate the longitudinal changes in striatal and extrastriatal dopamine D2 receptor binding in patients with early Huntington's disease.
• To correlate these changes with clinical and neuropsychological assessments.

Main Methods:

• Serial positron emission tomography (PET) scans using (11)C-raclopride, a D2 dopamine receptor ligand, were performed on 12 HD patients.
• Scans were acquired at baseline and at approximately 29 and 42 months.
• Statistical Parametric Mapping (SPM) was used to analyze regional changes in binding potential (BP) and compare with age- and sex-matched controls.

Main Results:

• A significant annual loss of striatal D2 receptor binding potential (BP) of approximately 4.8-5.2% was observed over 3 years.
• SPM revealed significant baseline reductions in both striatal and extrastriatal areas (amygdala, temporal, and frontal cortex) in HD patients compared to controls.
• Progressive striatal, frontal, and temporal D2 BP reductions were confirmed over time, correlating with planning task performance but not with motor scores or other cognitive measures.

Conclusions:

• Serial (11)C-raclopride PET demonstrates a linear progression of D2 receptor loss in the striatum and extrastriatal regions over 3 years in early HD.
• The observed D2 receptor loss progresses independently of motor symptom severity in the early stages.
• Neuropsychological measures, particularly planning abilities, show some correlation with D2 receptor binding, suggesting a role in cognitive decline.